Neurology High-Yield: What the FNP Boards Always Test
Clinical High-Yield · 11 min read · April 28, 2026
Neurology is one of the most feared sections of the FNP boards — and one of the most predictable. The boards are not testing your ability to manage a complex stroke workup or titrate anti-epileptic medications in a hospital setting. They are testing whether you can recognize a dangerous presentation, initiate appropriate first-line management, and know when the patient needs to leave your office immediately.
That's a much narrower target than most students realize. Here's what you actually need to know.
Headaches: The Three You Must Know Cold
The FNP boards test headaches almost exclusively through three presentations: migraine, tension-type, and the headache that is not benign.
Migraine is the most tested. The classic presentation is a unilateral, throbbing headache lasting 4–72 hours, associated with nausea, photophobia, and phonophobia. Roughly 25% of migraines are preceded by an aura — typically visual (scotoma, zigzag lines, visual field loss) but occasionally sensory or motor. For the boards, know the first-line abortive treatment: triptans (sumatriptan is the prototype) for moderate-to-severe attacks, NSAIDs or acetaminophen for mild attacks. For prophylaxis, know the four first-line classes: beta-blockers (propranolol, metoprolol), tricyclic antidepressants (amitriptyline), anticonvulsants (topiramate, valproate), and CGRP antagonists (the newer class — erenumab is the prototype).
Tension-type headache presents as bilateral, non-throbbing, pressure-like pain without nausea or photophobia. It is the most common headache type but rarely the focus of a board question. When it does appear, the answer is usually NSAIDs or acetaminophen, and reassurance.
The headache that is not benign is where the boards test clinical judgment. The red flags you must know: sudden onset reaching maximum intensity within seconds (thunderclap headache — subarachnoid hemorrhage until proven otherwise), headache with fever and neck stiffness (meningitis), headache with papilledema or focal neurological deficits (mass lesion or increased intracranial pressure), new headache in a patient over 50 (giant cell arteritis — check ESR and CRP immediately), and headache that is the "worst of my life" in a patient with no prior headache history. Any of these presentations requires urgent evaluation, not empiric treatment.
Board Pearl: A patient presents with sudden-onset severe headache described as "the worst headache of my life." The correct next step is not CT scan — it is emergent transfer to the ED. The boards test whether you recognize the urgency, not whether you order the right imaging.
Seizures: First-Time vs. Established Epilepsy
The boards test two distinct seizure scenarios: the patient presenting after a first seizure, and the patient with established epilepsy who is having breakthrough seizures.
First seizure evaluation requires ruling out reversible causes before diagnosing epilepsy. The workup includes blood glucose (hypoglycemia is the most common reversible cause), electrolytes (hyponatremia, hypocalcemia), CBC (infection), toxicology screen, and brain imaging. An EEG is appropriate but does not need to happen in the acute setting. Not every first seizure requires anti-epileptic drug (AED) therapy — the decision depends on the risk of recurrence, which is higher with an abnormal EEG, a structural brain lesion, or a nocturnal seizure.
Established epilepsy questions typically test AED selection and side effects. Know these pairings: valproate is first-line for generalized epilepsy but is teratogenic (neural tube defects) and requires monitoring for hepatotoxicity and pancreatitis. Lamotrigine is preferred in women of childbearing age. Phenytoin is an older agent with a narrow therapeutic window, zero-order kinetics (small dose increases cause disproportionate toxicity), and gingival hyperplasia as a classic side effect. Carbamazepine is first-line for focal (partial) seizures and trigeminal neuralgia, but it is a strong CYP450 inducer and can cause Stevens-Johnson syndrome.
Driving restrictions after a seizure are a common board question. Most states require a seizure-free period (typically 3–12 months) before a patient can legally drive. The FNP's role is to counsel the patient and document that counseling.
Stroke: Recognition and the Time Window
The boards test stroke recognition, not stroke management. Your job as an FNP is to identify the presentation, call 911, and get the patient to a stroke center within the treatment window.
The classic stroke presentation is sudden-onset focal neurological deficit: unilateral weakness or numbness, facial droop, speech difficulty (aphasia or dysarthria), visual disturbance, or ataxia. The FAST mnemonic (Face, Arms, Speech, Time) is the clinical tool — know it cold.
TIA vs. stroke: A transient ischemic attack (TIA) is a stroke that resolves completely within 24 hours (by definition) with no infarction on imaging. The boards test that a TIA is a medical emergency — not a "mini-stroke" to be managed outpatient. The ABCD2 score (Age, Blood pressure, Clinical features, Duration, Diabetes) stratifies TIA risk; high-risk patients need urgent hospitalization.
Hemorrhagic vs. ischemic: The boards do not expect you to differentiate these clinically — that's what CT is for. What they do expect: do not give tPA (thrombolytics) without imaging, because giving tPA to a hemorrhagic stroke is fatal. The treatment window for tPA in ischemic stroke is 3–4.5 hours from symptom onset.
Parkinson's Disease: Diagnosis and First-Line Treatment
Parkinson's disease is a clinical diagnosis — there is no definitive test. The four cardinal features are tremor (resting, "pill-rolling," improves with movement), rigidity (cogwheel), bradykinesia (slowness of movement), and postural instability. The boards test that you need at least two of these four features, with bradykinesia being the most specific.
Treatment: Levodopa/carbidopa (Sinemet) is the most effective treatment and the gold standard for symptom control. Carbidopa prevents peripheral conversion of levodopa to dopamine, reducing nausea and allowing more levodopa to cross the blood-brain barrier. Dopamine agonists (pramipexole, ropinirole) are an alternative in younger patients to delay levodopa initiation and reduce the risk of motor fluctuations. MAO-B inhibitors (selegiline, rasagiline) are used as adjunctive therapy.
Key side effects to know: levodopa causes dyskinesias (involuntary movements) with long-term use. Dopamine agonists cause impulse control disorders (gambling, hypersexuality) — this is a board favorite. Anticholinergics (benztropine) are used for tremor but are contraindicated in older adults due to cognitive side effects.
Multiple Sclerosis: Presentation and Management Principles
MS is a demyelinating disease of the CNS that classically presents in young women (20–40 years old) with episodes of neurological dysfunction separated in time and space. The most common presentations: optic neuritis (painful vision loss, afferent pupillary defect), Lhermitte's sign (electric shock sensation down the spine with neck flexion), internuclear ophthalmoplegia (impaired adduction of the ipsilateral eye with nystagmus in the contralateral eye on lateral gaze), and bladder dysfunction.
Diagnosis: MRI with gadolinium is the imaging of choice — it shows periventricular white matter lesions ("Dawson's fingers"). Lumbar puncture shows oligoclonal bands in CSF (present in >90% of MS patients).
Treatment: Acute relapses are treated with high-dose IV methylprednisolone. Disease-modifying therapy (DMT) is the long-term management — the boards do not expect you to know specific DMT agents in detail, but they do expect you to know that DMT reduces relapse frequency and slows disability progression, and that all patients with relapsing-remitting MS should be on DMT.
Peripheral Neuropathy: The Diabetic Foot
Peripheral neuropathy questions on the boards almost always involve diabetic neuropathy. The presentation is symmetric, distal, "stocking-glove" distribution of numbness, tingling, and burning pain — worse at night. The boards test the treatment: first-line agents are pregabalin (Lyrica), gabapentin (Neurontin), duloxetine (Cymbalta), and tricyclic antidepressants (amitriptyline). Opioids are not first-line.
The boards also test foot care counseling for diabetic patients: daily foot inspection, proper footwear, avoidance of barefoot walking, and regular monofilament testing (10-g Semmes-Weinstein monofilament) to assess protective sensation.
The Bottom Line
Neurology on the FNP boards rewards pattern recognition and clinical urgency over encyclopedic knowledge. Know your headache red flags. Know your seizure workup. Know when stroke is a 911 call. Know your Parkinson's treatment and its side effects. Know MS presentation and the role of MRI. Master these five areas and you will handle the neurology section with confidence.
→ Explore the FNP Board Review Book — every neurology topic covered with board-focused clinical pearls and practice questions.